Presenter: Kenneth Bloom, M.D., F.A.C.P. | CMO, Advanced Pathology and Genomic Services, Invicro
Developing highly accurate and precise assays that maintain tissue morphology to understand contextual relationships remains essential in drug discovery. Namely, this is critically important in immuno-oncology which requires an understanding of immune cell interactions within the tumor microenvironment (TME). Despite advances made with other commercially available fluorescent-based detection methods, many require signal amplification and do not provide adequate sensitivity, thus leading to higher false negatives, which can adversely impact trial design, including the establishment of treatment cutoff values.
Quanticell™, a novel fluorescent nanoparticle-based detection technology represents a reimagined approach to interrogate drug targets and large molecule therapeutics across a wider dynamic range in clinical biopsies.
During this webinar, the presenter will:
Present HER-2 low immunostaining data generated from formalin-fixed paraffin embedded (FFPE) breast cancer tissue microarrays (TMA) using Quanticell to demonstrate its potential in improving predictions to antibody-drug conjugates (ADC) and other targeted therapies
Dr. Bloom serves as the Chief Medical Officer (CMO) for Advanced Pathology and Genomic Services at Invicro and Ambry Genetics, both Konica Minolta precision medicine companies. Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine and bioinformatics. His role at Konica Minolta is to expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.
Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a startup to the eventual acquisition by GE Healthcare.